Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC
oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]
AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.
- Experts on site: RAS inhibitors reshape NSCLC treatment landscape (5)
- Industry moves: BridgeBio reshuffles as KRAS race heats up (1)
- On the AACR floor: zoldonrasib delivers durable G12D responses (4)
- Perioperative and biomarker research reshapes precision care in NSCLC (4)
- All Other Stories
Experts on site: RAS inhibitors reshape NSCLC treatment landscape
Industry moves: BridgeBio reshuffles as KRAS race heats up
On the AACR floor: zoldonrasib delivers durable G12D responses
Perioperative and biomarker research reshapes precision care in NSCLC
All Other Stories
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 12 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Rural Health, Infant Health, Gene Therapy, Wildlife and look for the RSS link.
StackHealth Time Machine